| 0.22 -0.012 (-5.09%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.33 | 1-year : | 0.38 |
| Resists | First : | 0.28 | Second : | 0.33 |
| Pivot price | 0.24 |
|||
| Supports | First : | 0.2 | Second : | 0.17 |
| MAs | MA(5) : | 0.23 |
MA(20) : | 0.24 |
| MA(100) : | 0.33 |
MA(250) : | 0.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 12.3 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 2.09 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VIRI ] has closed above bottom band by 8.4%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.24 - 0.24 | 0.24 - 0.24 |
| Low: | 0.21 - 0.21 | 0.21 - 0.22 |
| Close: | 0.22 - 0.22 | 0.22 - 0.22 |
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Tue, 23 Jul 2024
Virios Therapeutics Announces Completion of Enrollment in - GlobeNewswire
Tue, 23 Jul 2024
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center - StockTitan
Mon, 20 May 2024
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Mon, 20 May 2024
Why Is Virios Therapeutics (VIRI) Stock Down 44% Today? - InvestorPlace
Mon, 13 May 2024
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 6.7 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 312 (K) |
| Shares Short P.Month | 335 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.8 % |
| Return on Equity (ttm) | -117.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 0 |
| Price to Book value | 1.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|